1/15
Looks like no tags are added yet.
Types of components in coagulation
• Zymogens - inactive enzyme that becomes active following specific proteolytic cleavage e.g. factors 7, 9, 10, 11 and 2 (prothrombin)
• Cofactors - help enzymes work efficiently e.g. factors 5, 8 and 3 (tissue factor)
• Substrate - protein acted upon to produce a new product e.g. fibrinogen (F1)
• Calcium - factor 4 (Ca2+) helps coagulation factors bind to suitable phospholipid surfaces and assemble complexes
• Transglutaminase - forms covalent bonds that stabilise fibrin e.g. factor 13a
Factor groups
• Prothrombin group - 2, 7, 9 and 10 plus protein C and S (vitamin K dependant)
• Fibrinogen group - fibrinogen (1), 5, 7 and 13 (acted upon by thrombin)
• Contact group - 11, 12, prekallikrein and HMWK - participate in contact activation and interact with kinin, complement and fibrinolytic systems
Extrinsic pathway
• Tissue factor (cofactor) binds to circulating F7 and its activated form F7a
• The TF-F7a complex, in the presence of calcium, activates F10 to F10a
• The complex also activates F9, feeding into the intrinsic tenase pathway and amplifying the response
Intrinsic pathway
• F12 is activated to F12a through contact activation (interaction with certain negatively charged surfaces)
• F12a activates F11 to F11a
• F11a activates F9 to F9a in the presence of calcium
• F9a combines with activated F8a (cofactor), calcium and negatively charged phospholipid surface on activated platelets to form the intrinsic tenase complex
• The tenase complex activated F10 to F10a
Kallikrein and HMWK
• F12 also activates prekallikrein into kallikrein which amplifies F12 activation
• HMWK is a cofactor for contact activation
• F12 can prolong the APTT but is not associated with increased bleeding tendency
• F13 deficiency can cause bleeding despite normal PT and APTT as these tests do not directly measure the final cross-linking step
Common pathway
• F10a combines with F5a (cofactor), calcium and a suitable phospholipid surface to form the prothrombinase complex
• Prothrombin (F2) is converted to thrombin (F2a)
• Thrombin converts fibrinogen (F1) into fibrin
• Thrombin also activates F13 to F13a, which cross-links fibrin
Cell based coagulation model
• Better explains how coagulation occurs in vivo, emphasises TF as the physiological trigger and the platelet surface reactions as the source of the thrombin burst
• Initial phase - tissue factor exposed on TF-bearing cells, small initial amount of thrombin produced
• Amplification phase - thrombin activated several targets, platelets become activated and expose the phospholipid surface, FV (also released from platelet granules) is activated to FVa, F8 is activated to F8a
• Propagation (thrombin burst) - the activated platelet surface now brings the essential components together
• Intrinsic tenase - F9a + F8a + calcium + phospholipid
• Prothrombinase - F10a + F5a + calcium + phospholipid
Haemophelia
• Haemophilia A - F8 deficiency
• Haemophilia B - F9 deficiency
• Haemophilia C - F11 deficiency, severity is variable
Vitamin K dependant factors
• Vitamin K is needed for the post-translational modification called gamma-carboxylation of certain glutamate residues in coagulation proteins
• This modification allows these proteins to bind calcium and attach to negatively charged phospholipid surfaces
• Without vitamin K these proteins may still be produced but have an impaired function
• Warfarin is a vitamin K antagonist